Signalling that it also sees promise in the targeted protein degradation space, Vertex has entered a four-year collaboration with Kymera Therapeutics to develop up to six small molecule protein degraders. The deal, worth potentially more than US$1 B, leverages Kymera’s Pegasus™ platform and Vertex’s scientific, clinical and regulatory capabilities to target previously undruggable diseases by harnessing the natural ubiquitin-proteasome system. Biogen, GSK, Pfizer and Roche have all expressed interest in the field in recent years.